AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the Aro...
October 13 2017 - 2:50AM
"We very much look forward to this new
collaboration with the England based Pathway Diagnostics for the
distribution of our TK 210 ELISA test", states Jan Stålemark,
AroCell CEO. "Pathway Diagnostics Ltd is a leading supplier of
specialist clinical and research diagnostics in the UK and was
established in 1998 to provide high quality in-vitro diagnostic
products and instrumentation to clinical, research and industrial
laboratories mainly in the UK and Ireland. Pathway Diagnostics are
highly focused on the needs of their customers and in providing the
highest quality products and service and therefore we consider them
as a perfect match for our TK 210 ELISA test."
The TK 210 ELISA test will be commercially
available immediately through Pathway Diagnostics in the UK and
Irish market.
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 08:50 CET
on 13 October 2017.
About
AroCell
AroCell AB
(publ) is a Swedish company that develops standardized modern blood
tests to support the prognosis and follow up of cancer patients.
AroCell's new technology is based on patented methods to measure
(Thymidine Kinase 1 (TK1) protein levels in a blood sample.
The TK 210 ELISA test provide valuable information
mainly about the condition of cancer patients. This may help
clinicians to optimize treatment strategies and estimate the risk
of recurrence of the tumor disease during monitoring of the
disease. AroCell (AROC) is listed at Nasdaq
First North and has about 2,500 shareholders. For more information,
please see www.arocell.com. Redeye AB is
AroCell's Certified Adviser.
Press Release Distribution
UK20171011_final
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Apr 2023 to Apr 2024